AbbVie (ABBV) vs Amgen (AMGN): Stock Comparison
Data as of November 7, 2026. Refreshed weekly from SEC filings and market data.
Amgen is cheaper on earnings, at 26.5 times against 49.3; Amgen keeps the higher net margin (24.1% against 15.7%); AbbVie grew revenue faster over the last year (10.7% against 8.2%); dividend yield is about the same (2.4% and 2.1%). AbbVie clears 2 of this site's 8 value filters and Amgen 3. Figures are as of November 7, 2026; each is on the page below with its source.
How do AbbVie and Amgen compare on the numbers?
| Measure | AbbVie (ABBV) | Amgen (AMGN) | Clearer lead |
|---|---|---|---|
| Share price | $291.31 | $460.42 | |
| Market value | $509 billion | $249 billion | |
| P/E ratio (trailing) | 49.3 | 26.5 | AMGN |
| PEG ratio | 3.95 | 5.89 | ABBV |
| Free-cash-flow yield | 3.7% | 4.1% | About the same |
| Net profit margin | 15.7% | 24.1% | AMGN |
| Revenue growth, last year | 10.7% | 8.2% | ABBV |
| Return on equity | 95.6% | 85.6% | ABBV |
| Debt to equity | 49.22 | 3.76 | AMGN |
| Dividend yield | 2.4% | 2.1% | About the same |
| Margin of safety (DCF) | -58.1% | -43.3% | AMGN |
| Value filters passed (of 8) | 2 | 3 | AMGN |
| Distance from 52-week high | -1.2% | -3.8% |
How have AbbVie and Amgen shares done against each other?
AbbVie 251Amgen 218
Each share price set to 100 on Nov 2021, to Nov 2026. Price only: dividends are not included.
From Nov 2021 to Nov 2026, AbbVie shares are up 151% and Amgen shares up 118%, so AbbVie has pulled ahead of Amgen by 33 points of the starting price. The deepest fall from a prior high in that window was 19% for AbbVie and 24% for Amgen.
| Period | AbbVie (ABBV) | Amgen (AMGN) |
|---|---|---|
| Last 1 year | +33.0% | +45.9% |
| Last 3 years | +106.3% | +68.8% |
| Last 5 years | +148.6% | +115.4% |
Which has grown faster, AbbVie or Amgen?
Over 5 years, AbbVie grew revenue 6.0% a year and earnings per share -2.8% a year; Amgen grew revenue 7.6% and earnings per share 2.9%. Its net margin averaged 12.8% at AbbVie and 20.9% at Amgen.
| Measure | AbbVie (ABBV) | Amgen (AMGN) |
|---|---|---|
| Latest fiscal year ended | Dec 2025 | Dec 2025 |
| Revenue, first year to latest | $45.8 billion to $61.2 billion | $25.4 billion to $36.8 billion |
| Revenue growth per year | 6.0% | 7.6% |
| Earnings per share, first year to latest | $2.72 to $2.36 | $12.31 to $14.23 |
| Earnings per share growth per year | -2.8% | 2.9% |
| Net margin, latest year | 6.8% | 21.0% |
| Net margin, average of the years | 12.8% | 20.9% |
| Free cash flow margin, latest year | 29.1% | 22.0% |
From each company's 10-K filings (SEC EDGAR), over its latest 5 years.
What growth does each share price assume?
| Measure | AbbVie (ABBV) | Amgen (AMGN) |
|---|---|---|
| Free cash flow growth the price implies | 19.7% a year | 17.1% a year |
| Free cash flow per share | $10.79 | $18.81 |
| Margin of safety on this site's DCF | -58.1% | -43.3% |
At $291.31, AbbVie's price implies free cash flow growth of 19.7% a year, fading to 2.5% over 10 years. That is more growth than the 8% baseline.
At $460.42, Amgen's price implies free cash flow growth of 17.1% a year, fading to 2.5% over 10 years. That is more growth than the 8% baseline.
The same model and baseline as every stock page. A price that asks for less growth is not a better company, only a lower bar to clear.
Where is each stronger?
Where AbbVie leads
- Lower PEG: 3.95 against 5.89
- Faster revenue growth last year: 10.7% against 8.2%
- Higher return on equity: 95.6% against 85.6%
- A higher free-cash-flow margin in its latest filed year: 29.1% against 22.0%
Where Amgen leads
- Lower P/E: 26.5 against 49.3
- Higher net margin: 24.1% against 15.7%
- Less debt for its equity: 3.76 against 49.22
- Higher margin of safety on this site's DCF: -43.3% against -58.1%
- More of the 8 value filters: 3 against 2
- Faster revenue growth over its filed record: 7.6% against 6.0%
- Faster earnings-per-share growth over its filed record: 2.9% against -2.8%
- A higher net margin in its latest filed year: 21.0% against 6.8%
- A higher average net margin: 20.9% against 12.8%
About the same on: free-cash-flow yield, dividend yield. A lead needs a clear gap (10% apart on a ratio, 1 point on a percentage), so a rounding difference never names a winner. A lead on one measure is not a verdict on the company.
How do the businesses differ?
AbbVie. AbbVie develops and sells prescription drugs, led by the immunology drugs Skyrizi and Rinvoq (which replaced Humira as growth drivers), along with Botox and other aesthetics products, cancer and neuroscience medicines.
Amgen. Amgen develops and sells biotech drugs for conditions including bone loss, cancer, heart disease and inflammation, and is developing an obesity drug.
Both are in the Biotechnology industry on this site.
What stands out about AbbVie
- Misses 4 of the 8 value filters. It fails Trailing P/E < 25 (49.26), PEG Ratio < 1.5 (3.95) and Price/Book < 8 (358.80) and 1 more; the other 2 pass and 2 were not evaluated.
- Strongest against peers: return on equity. At 96% (peer median 20%) it ranks 1st of 15 among pharma & biotech stocks this site tracks.
- Weakest against peers: debt / equity. At 49.22 (peer median 0.94) it ranks 15th of 15 among pharma & biotech stocks this site tracks.
What stands out about Amgen
- Misses 3 of the 8 value filters. It fails Trailing P/E < 25 (26.50), PEG Ratio < 1.5 (5.89) and Price/Book < 8 (17.34); the other 3 pass and 2 were not evaluated.
- Weakest against peers: debt / equity. At 3.76 (peer median 0.94) it ranks 14th of 15 among pharma & biotech stocks this site tracks.
- Balance sheet in the distress zone. Its Altman Z″-Score is 0.14; below 1.1 is the distress zone, 1.1 to 2.6 the grey zone.
Frequently asked questions about AbbVie and Amgen
Which is cheaper, AbbVie or Amgen?
On trailing earnings, Amgen is cheaper: AbbVie trades at 49.3 times and Amgen at 26.5 times. On free cash flow, the yields are 3.7% and 4.1%. Cheaper is not the same as better value: read the growth each price assumes below.
Which pays the higher dividend, AbbVie or Amgen?
Their yields are about the same: AbbVie 2.4% and Amgen 2.1% over the last year.
Which has grown faster, AbbVie or Amgen?
Over their latest filed five years, AbbVie grew revenue 6.0% a year and Amgen 7.6%; earnings per share grew -2.8% and 2.9% a year.
Which has more debt, AbbVie or Amgen?
AbbVie has more debt for its equity: debt to equity is 49.22 for AbbVie and 3.76 for Amgen. A very high figure can also come from buybacks that shrank equity.
Which is more profitable, AbbVie or Amgen?
Amgen keeps more of each sales dollar as profit: 15.7% for AbbVie and 24.1% for Amgen, with a return on equity of 95.6% and 85.6%.
Which passes more of the 8 value filters?
Amgen clears more: AbbVie 2 of 8 and Amgen 3 of 8. The filters are this site's own value rules, not a prediction.
Where do these numbers come from?
Prices, ratios and yield are from this site's weekly data as of November 7, 2026; growth and margins by year are from each company's 10-K filings (sources on AbbVie and Amgen). The DCF is the same model on every stock page. See Editorial Standards. Educational, not investment advice.